NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
Clinical Trials
340 trialsNCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT04285268 2026-01-30
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Rutgers, The State University of New Jersey
Phase 2 Withdrawn
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT03135743 2026-01-16
LYMPHOSYNCHRO
Centre Hospitalier Universitaire, Amiens
Withdrawn
NCT06650839 2026-01-07
POC for the Treatment of Subjects With Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy
Cardiawave SA
Phase NA Withdrawn
NCT04091009 2025-12-31
Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms
Massachusetts General Hospital
Phase 4 Withdrawn
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT05263739 2025-09-12
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Shanghai Escugen Biotechnology Co., Ltd
Phase 1 Withdrawn
NCT06005649 2025-08-08
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT06009107 2025-08-08
B-ALL
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT06013904 2025-07-04
Difficult PIV Placement in the Pediatric ED
University of Texas at Austin
Phase NA Withdrawn
NCT05538988 2025-06-27
BIOSELECT
AHS Cancer Control Alberta
Phase 1/2 Withdrawn
NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT05106192 2025-06-12
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT06839872 2025-06-05
BOSS
AstraZeneca
Phase 2 Withdrawn
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04694560 2025-05-16
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Memorial Sloan Kettering Cancer Center
Withdrawn
NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT02548468 2025-05-02
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Thomas Jefferson University
Phase 1 Withdrawn
NCT03288818 2025-04-29
Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides
Thomas Jefferson University
Phase 2 Withdrawn
NCT06238531 2025-03-13
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT04781855 2025-02-28
Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT04148742 2025-02-25
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Dizal Pharmaceuticals
Phase 1/2 Withdrawn
NCT03169790 2025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT03939585 2024-12-05
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05487495 2024-11-14
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Phase 1 Withdrawn
NCT06003179 2024-11-12
LOKI
University Health Network, Toronto
Phase 1 Withdrawn
NCT04523623 2024-10-26
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
Washington University School of Medicine
Phase NA Withdrawn
NCT03417765 2024-10-24
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
VectivBio AG
Phase 1/2 Withdrawn
NCT05134740 2024-10-22
pediTACTAL
Baylor College of Medicine
Phase 1 Withdrawn
NCT05521178 2024-10-15
Cardiotoxicities in Patients Receiving BTKi
Dana-Farber Cancer Institute
Withdrawn
NCT04575064 2024-10-09
An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY
Klinikum Bremen-Mitte, gGmbH
Phase 2/3 Withdrawn
NCT02298816 2024-10-03
HMvax-Regist
Wake Forest University Health Sciences
Withdrawn
NCT04322084 2024-09-25
Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)
St. Jude Children's Research Hospital
Withdrawn
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT04996745 2024-08-26
Taking POSNA's OrthoKids to the People
Louisiana State University Health Sciences Center in New Orleans
Phase NA Withdrawn
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05966233 2024-05-21
FIL_POLARDHAP
Fondazione Italiana Linfomi - ETS
Phase 2 Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06400264 2024-05-06
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT05465876 2024-04-04
PACE-CLL
Sunnybrook Health Sciences Centre
Phase 2 Withdrawn
NCT06205290 2024-04-02
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn